Altimmune Inc
3G0
Company Profile
Business description
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
Contact
910 Clopper Road
Suite 201S
GaithersburgMD20878
USAT: +1 240 654-1450
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
57
Stocks News & Analysis
stocks
Big 4 earnings: Morningstar analysts form view on impact of slowing housing market
Big 4 bank maintains Fair Value, Short-term earnings not material enough to shift valuation for key player
stocks
ASX healthcare share remains cheap despite mixed earnings result
Shares in Aussie listed healthcare name undervalued post earnings.
stocks
Wide moat ASX share beats earnings guidance
Wide moat share continues to grow despite a challenging residential construction market.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,404.70 | 0.80 | -0.01% |
| CAC 40 | 8,674.94 | 40.00 | -0.46% |
| DAX 40 | 26,331.07 | 60.35 | -0.23% |
| Dow JONES (US) | 53,839.93 | 48.08 | 0.09% |
| FTSE 100 | 10,833.15 | 11.04 | -0.10% |
| HKSE | 25,440.17 | 212.65 | -0.83% |
| NASDAQ | 26,579.09 | 133.64 | 0.51% |
| Nikkei 225 | 67,524.06 | 553.84 | 0.83% |
| NZX 50 Index | 13,737.66 | 123.00 | -0.89% |
| S&P 500 | 7,747.87 | 19.67 | 0.25% |
| S&P/ASX 200 | 9,209.40 | 2.20 | -0.02% |
| SSE Composite Index | 3,946.68 | 12.58 | 0.32% |